Format

Send to

Choose Destination
See comment in PubMed Commons below
Methods Mol Biol. 2012;821:251-65. doi: 10.1007/978-1-61779-430-8_15.

The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia.

Author information

1
Drug Discovery, Intellikine Inc., La Jolla, CA 92037, USA.

Abstract

Preclinical evaluation of candidate anticancer compounds requires appropriate animal models. Most commonly, solid tumor xenograft systems are employed in which immunocompromised mice are implanted with human cancer cell lines. Genetically engineered mouse models of solid tumors are also frequently employed. Both of these approaches can also be applied to studies of hematological malignancies. In this chapter, we describe three types of mouse models of leukemia driven by the human BCR-ABL oncogene. We also discuss the application of these models to preclinical testing of active-site TOR inhibitors, a novel class of compounds that selectively target the ATP-binding pocket of the target of rapamycin (TOR) kinase.

PMID:
22125070
DOI:
10.1007/978-1-61779-430-8_15
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center